HIGHLIGHTS
- who: Hye-Sol Jung et al. from the Department of Surgery and Research Institute, College of Medicine, National University have published the research work: Oncologic Benefits of Neoadjuvant Treatment versusUpfront Surgery in Borderline Resectable PancreaticCancer: A Systematic Review and Meta-Analysis, in the Journal: Cancers 2022, 4360 of 11/02/2022
- what: In this systematic review, neoadjuvant chemoradiotherapy did not improve patients` survival compared with neoadjuvant chemotherapy alone.
- how: The following data were collected title first author and publication year.
SUMMARY
Most studies had retrospective designs; a few studies . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.